Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Nerlynx (neratinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.